Financial Performance Summary
Q2 FY27 Financial Highlights
- Revenue from operations: ₹2,603 Cr, up 36% YoY
- EBITDA: ₹578 Cr, up 78% YoY
- EBITDA margin: 22%
- Profit After Tax: ₹335 Cr, up 81% YoY
H1 FY27 Financial Highlights
- Revenue from operations: ₹4,753 Cr, up 31% YoY (vs ₹3,621 Cr in H1 FY26)
Segment-wise Performance Breakdown
India Branded Business
- Q2 FY27 revenue: ₹725 Cr, up 14% YoY (vs ₹639 Cr in Q2 FY26)
- H1 FY27 revenue: ₹1,367 Cr, up 10% YoY (vs ₹1,238 Cr in H1 FY26)
- Strong growth in Gynecology, Cardiology, Gastrology, and Ophthalmology therapies
- Animal Health segment grew 23% for the quarter
International Business - US Formulations
- Q2 FY27 revenue: ₹1,003 Cr, up 77% YoY (vs ₹566 Cr in Q2 FY26)
- H1 FY27 revenue: ₹1,781 Cr, up 64% YoY (vs ₹1,089 Cr in H1 FY26)
- 3 new product launches in the US market during the quarter
- 1 ANDA approval received during the quarter
- Cumulative ANDA approvals: 245
International Business - Ex-US
- Q2 FY27 revenue: ₹440 Cr, up 12% YoY (vs ₹392 Cr in Q2 FY26)
- H1 FY27 revenue: ₹823 Cr, up 14% YoY (vs ₹719 Cr in H1 FY26)
API Business
- Q2 FY27 revenue: ₹436 Cr, up 39% YoY (vs ₹314 Cr in Q2 FY26)
- H1 FY27 revenue: ₹782 Cr, up 36% YoY (vs ₹575 Cr in H1 FY26)
Management Commentary
Mr. Pranav Amin, Managing Director, commented: "We delivered another quarter of strong, broad-based growth and improved profitability, reflecting consistent execution across markets. Our US business delivered an exceptional performance, driven by strong volume growth and new launches, while India regained momentum as Ex-US and API continued their growth trajectories. In India Branded, improving momentum in chronic therapies is strengthening the quality of growth, while in US Branded, we are encouraged by the traction building across our existing portfolio. Following a strong first half, we are well positioned to sustain growth and create long-term value for all our stakeholders."
Investor Communication
Alembic Pharmaceuticals Limited hosted an investor call on November 04, 2026, at 5:00 pm IST where senior management discussed the company's performance and answered participant questions.
Company Background
Alembic Pharmaceuticals Limited is a vertically integrated research and development pharmaceutical company that has been operating since 1907. The company manufactures and markets generic pharmaceutical products worldwide with state-of-the-art research and manufacturing facilities approved by regulatory authorities including the US FDA. Alembic is one of the leaders in branded generics in India.